• LinkedIn - White Circle

The Rare Advocacy Movement (RAM) is a group of patient advocacy professionals dedicated to the overall advancement of the rare disease patient advocacy professional ecosystem and landscape. Membership and participation in RAM is subject to the observance of the established Code of Conduct for Membership ("Code of Conduct") and the acceptance of the established and adopted RAM Process Document. All members and affiliates of RAM vow to abide by the established Code of Conduct. Any RAM member or affiliate who may violate the Code of Conduct in parts and/or in its entirety will be subject to immediate removal from the RAM membership and/or affiliation.

Christopher Missling
Christopher U. Missling, PhD is President and CEO of Anavex Life Sciences Corp, has over 20 years of healthcare industry experience within large pharmaceutical companies and the biotech industry. Prior to joining Anavex, he served as the Chief Financial Officer of Curis and ImmunoGen. In addition, at Aventis (now Sanofi), Christopher’s work is dedicated to finding potential cures for rare diseases especially for neurodevelopmental diseases, like Rett syndrome, Fragile X, Angelman’s syndrome, infantile spasms as well as neurodegenerative diseases. Dr. Missling is working with his team to advance new potential treatments through clinical trials by involving the respective advocacy groups early on. Dr. Missling has an MS and PhD from the University of Munich in Chemistry and an MBA from Northwestern University Kellogg School of Management and WHU Otto Beisheim School of Management.